UPDATE 3-Indonesia turns to China for more vaccines after AstraZeneca delays

Indonesia is in talks with China to secure as many as 100 million COVID-19 vaccine doses to plug a gap in deliveries after delays in arrivals of AstraZeneca shots, the health minister said on Thursday.

Reuters | Updated: 09-04-2021 09:03 IST | Created: 09-04-2021 09:03 IST
UPDATE 3-Indonesia turns to China for more vaccines after AstraZeneca delays

Indonesia is in talks with China to secure as many as 100 million COVID-19 vaccine doses to plug a gap in deliveries after delays in arrivals of AstraZeneca shots, the health minister said on Thursday. Indonesia would receive 20 million doses of the AstraZeneca vaccine via a bilateral deal in 2021, instead of 50 million initially agreed, Health Minister Budi Gunadi Sadikin told a parliamentary hearing.

The remaining 30 million doses were due to be shipped by the second quarter of 2022, he said. Budi said the government had "embarked on a discussion with the Chinese government to ask for an additional 90-100 million (doses)".

"We're also asking for vaccines from the U.S. when they're done with their own vaccinations and sell their vaccines overseas." Besides AstraZeneca, Indonesia relies heavily on vaccines produced by China's Sinovac Biotech for inoculations which began in January. It aims to reach 181.5 million people within a year in a bid to reach herd immunity.

Sinovac has supplied about 56 million doses so far. Indonesia was also due to receive 54 million doses of the AstraZeneca vaccine in phases via the COVAX sharing scheme, though Budi said Indian export restrictions would delay shipments in April.

"That's something that we cannot accept and we're negotiating with AstraZeneca. So that's 100 million doses of vaccine whose schedule remains unclear," he said. In response, AstraZeneca Indonesia referred Reuters to an April 2 statement in which the company said it aimed to start first deliveries in June.

Indonesia has also launched a private vaccination programme for companies to buy government-procured vaccines for their staff. State-owned company Bio Farma had started negotiations with China's Sinopharm and Cansino, along with the producer of Russia's Sputnik V, for vaccines for the private programme, Bio Farma chief executive Honesti Basyir told the parliamentary hearing.

The Southeast Asian country has been struggling to control one of Asia's worst epidemics, with 1.55 million cases and 42,200 deaths. It has administered at least one vaccine shot to more than 9.22 million people. European and British regulators said on Wednesday they had found possible links between AstraZeneca's vaccine and very rare cases of blood clots, but reaffirmed the vaccine's importance in protecting people against COVID-19. (Additional Reporting by Nilufar Rizki Editing by Ed Davies, Nick Macfie)

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)


TRENDING

OPINION / BLOG / INTERVIEW

Viral variants and vaccine nationalism pose two-pronged threat to Covid victory

... ...

Tracking Fintech during COVID-19: Harnessing power of technology

Its abundantly clear now that as fintech cements its place in the financial sector, accelerated further by the COVID-19 pandemic, it could open the sector to new possibilities by harnessing the power of technology to deliver financial ...

Tectonic turns: How technology shaped healthcare over the decades

Tracing an episodic evolution, with technology at the interface of human and his health....

World Water Day sees crises of inequality in countries both rich and poor

... ...

Videos

Latest News

Demarcation Board urged to work with district development committees

The Portfolio Committee on Cooperative Governance and Traditional Affairs has called on the Municipal Demarcation Board MDB to commit to ensuring that the demarcation of municipal boundaries results in the creation of sustainable municipali...

Morgan Stanley profit blows past estimates on dealmaking boom

Morgan Stanley reported a big jump in quarterly profit on Friday that comfortably beat expectations, as a global dealmaking boom boosted investment banking and heightened trading activity lifted its institutional securities division.Morgan ...

Johnson & Johnson asked rival COVID-19 vaccine makers to probe clotting risks - WSJ

Johnson Johnson had reached out to rival COVID-19 vaccine makers to join in an effort to study the risks of blood clots, the Wall Street Journal reported on Friday, citing people familiar with the matter.AstraZeneca, which had been buffete...

Woman can't be denied right to be considered for employment because of nature of work: Kerala HC

The Kerala High Court on Friday observed that a woman who is fully qualified cannot be denied of her right to be considered for employment on the grounds that she is a woman and because the nature of the employment would require her to work...

Give Feedback